GlassScriptPhysician profile
Nicole M King
NPI 1144653312
$9,209.87
in general payments reported to CMS, 2019-2025
34 companies · $509 in 2025
The $509 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,263 · 2022: $2,552 · 2023: $3,206 · 2024: $1,679 · 2025: $509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,283 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,282.55 |
| Education | $111.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,298.77 | 2021-2025 | |
| Allergan, INC. | $1,541.78 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $795.93 | 2022-2024 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $768.20 | 2021-2025 | Stelara, Tremfya |
| Genzyme Corporation | $503.87 | 2022-2024 | |
| Ardelyx, INC. | $278.93 | 2022-2024 | Ibsrela |
| Qol Medical, LLC | $269.53 | 2021-2023 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $251.13 | 2022-2024 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $250.41 | 2021-2025 | Xifaxan, Plenvu |
| Nestle Healthcare Nutrition INC. | $214.78 | 2022-2023 | |
| Aimmune Therapeutics, INC. | $210.76 | 2023-2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $205.63 | 2024 | Voquezna |
| Celgene Corporation | $202.30 | 2022-2024 | Zeposia |
| Pfizer INC. | $180.02 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $177.95 | 2021-2023 | Dificid, Zinplava |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $144.91 | 2025 | Rezdiffra |
| Ferring Pharmaceuticals INC. | $117.35 | 2021-2024 | Rebyota, Clenpiq |
| Braintree Laboratories, INC. | $98.98 | 2022-2023 | Sutab |
| Evoke Pharma, INC. | $95.46 | 2021-2024 | Gimoti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.74 | 2023-2024 | Cyltezo |
| Ironwood Pharmaceuticals, INC | $87.53 | 2021-2024 | |
| Intercept Pharmaceuticals, INC. | $82.50 | 2022-2023 | Ocaliva |
| Daiichi Sankyo INC. | $56.12 | 2021-2023 | Injectafer |
| Gilead Sciences, INC. | $44.70 | 2022-2024 | |
| Lilly USA, LLC | $37.20 | 2024 | Omvoh |
| Vivus LLC | $36.17 | 2021-2025 | Qsymia |
| Alexion Pharmaceuticals, INC. | $34.53 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $33.83 | 2024 | Iqirvo, Bylvay |
| Mylan Institutional INC. | $24.37 | 2023 | Hulio |
| Amgen INC. | $17.43 | 2023 | Amjevita |
| Sandoz INC. | $15.25 | 2024 | Hyrimoz |
| Organon LLC | $14.67 | 2023 | Hadlima |
| Redhill Biopharma INC. | $13.72 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $13.42 | 2024 | Breztri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.